Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS.
Neuromyelitis optica spectrum disorder: 2-deoxy-2-[(18)f]fluoro-d-glucose positron emission tomography findings.
The Submaximal Clinical Exercise Tolerance Test (SXTT) to Establish Safe Exercise Prescription Parameters for Patients with Chronic Disease and Disability.
Treatment of multiple sclerosis with anti-CD20 antibodies.
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
The INCAT disability score: A critical analysis of its measurement properties.
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
Raloxifene Suppresses Experimental Autoimmune Encephalomyelitis and NF-κB-Dependent CCL20 Expression in Reactive Astrocytes.
Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis.
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
A Herpes Simplex Virus-Derived Replicative Vector Expressing LIF Limits Experimental Demyelinating Disease and Modulates Autoimmunity.
Galectin-1 for neuroprotection?
Helminth therapy and multiple sclerosis.
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis.
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Pilates based core stability training in ambulant individuals with multiple sclerosis: Protocol for a multi-centre randomised controlled trial.
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE(R) Patent
Excess of melanocytic nevi in a patient treated with natalizumab for multiple sclerosis.
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging.

Pages